Sign in
CompletedPhase 2

Beta-glucan and Immune Response to Influenza Vaccine

Key facts

Who runs it
University of Florida
Where
Gainesville, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
78 people enrolled
Started
18 Jul 2022
Ended
28 Aug 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Influenza Vaccine
  • Beta-glucan
  • Placebo
Record updated
6 November 2025

Who can take part

Age
50 years to 100 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Adult volunteers ≥ 50 years of age
  • Planning to be vaccinated for influenza
  • Have been immunized for COVID-19
  • Willing and able to provide written informed consent in English
  • Willing and able to comply with all the study-related procedures, including attending to study visits for blood draw, taking the influenza vaccine, intake of the study supplement, and completing study questionnaires

Who cannot take part

  • Have an immune system alteration because of an underlying illness (e.g., autoimmune disease) or immune-suppressing treatment (e.g., steroids (last 30 days); cytotoxic drugs, medical surgery, or radiation therapy during the 6 months, previous to enrollment)
  • Have a history of a severe reaction or hypersensitivity following vaccination with influenza vaccine, vaccination with any other vaccine containing the same substances, or intake of the study product
  • Demonstrate an inability to comply with the study-related procedures
  • Be concurrently participating in a clinical trial that, in the judgement of the investigator, would interfere with the evaluation of the study outcomes

Where in United States

  • Food Science and Human Nutrition Department, University of FloridaGainesville, United States

About the trial

What the trial wants to find out

This trial in healthy adults will determine the effects of beta-glucan, a dietary fiber supplement isolated from baker's yeast, on immune response to the influenza vaccine.

The 2 groups in the trial

  • Beta-glucanTreatment being tested

    500 mg/day beta-glucan

    Treatment: Influenza Vaccine and Beta-glucan

  • PlaceboPlacebo, for comparison

    500 mg/day cellulose

    Treatment: Influenza Vaccine and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Yeast-derived Beta-glucan Supplementation on Antibody Response Following Influenza Vaccination: A Randomized, Placebo-controlled Study (M-Unity)
Publications
Record updated
6 November 2025